RIFADIN
LOE ApproachingNDAORALCAPSULE
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
RIFADIN by Sanofi is mechanism of action rifampin inhibits dna-dependent rna polymerase activity in susceptible mycobacterium tuberculosis organisms. Approved for asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx, meningococcal infection because of the possibility of the rapid emergence of resistant organisms, the treatment of all forms of tuberculosis. First approved in 1971.
Drug data last refreshed 2d ago
Mechanism of Action
Mechanism of Action Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Worked on RIFADIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.